We observed an extremely low RSV pneumonia fatality rate in contrast to that reported in the literature. Perhaps due to strict control of nosocomial transmission, our cohort tended to contract RSV late, which might account for better outcomes. Our low incidence of NIPCs is intriguing, and could be biased by the fact that 66% of our cohort was on 2 immunosuppressors. Our findings support prompt treatment of high-risk patients with inhaled ribavirin/IVIG to diminish early RSV-related mortality and morbidity.
Background: Diarrhea, abdominal pain and fever are common among patients undergoing hematopoietic stem cell transplant (HCT), but such symptoms are also typical with foodborne infections. The burden of disease caused by foodborne infections in patients undergoing HCT is unknown. We sought to describe the incidence of posttransplant bacterial foodborne infections in a single-center population of HCT recipients. Methods: We reviewed all patients who received a HCT at the Fred Hutchinson Cancer Research Center in Seattle, WA from 2001 to 2011. Data were collected retrospectively using center databases, which include information from transplant, on-site examinations, outside records, and collected laboratory data. Patients were considered to have a bacterial foodborne illness if Campylobacter jejuni/coli, Salmonella, Shigella, Yersinia or Listeria species were isolated in culture; patients with evidence of non-foodborne origin for infection were excluded. All post-transplant events were classified as early ( 100 days post-transplant) or late (>100 days). Results: A total of 18/4404 (0.4%) patients developed a posttransplant bacterial foodborne illness ( Figure 1 ). Patients had a mean age at infection of 45.8 years (range 1 e 68), and the majority were adults 18 years of age (n¼14 [78%]) and male gender (n¼13, [72%]). Most cases occurred in patients who had undergone an allogeneic transplant (n¼12 [67%]). These infectious episodes occurred at a median of 87.5 days after transplant (IQR 19, 367) . The overall incidence rate post-transplant was 0.34 per 100,000 patient days, and 1.9 per 100,000 in the early post-transplant period. Bacterial foodborne infections occurred evenly between the early and late periods (n¼9 early, n¼9 late). The most frequent pathogen detected was Campylobacter (n¼9 [50 %]) followed by Salmonella (n¼5 [28%]), Yersinia (n¼2 [11%]) and Listeria (n¼2 [11%]); no cases of Shigella were detected. Diagnoses were made in most patients through positive stool cultures (n¼13 [72%]), while a smaller proportion were first positive through blood cultures (n¼4 [22%]); one patient was positive simultaneously at both sites. Mortality due to bacterial foodborne illness was not observed during follow-up. Conclusions: Our large single-center study indicates that bacterial foodborne infections were a rare complication following HCT. These data provide important baseline incidence for future studies evaluating dietary interventions in HCT patients. Objective: Invasive fungal infections are a cause of mortality in pediatric allogeneic hematopoietic cell transplantation (allo-HCT) recipients. Prophylaxis with triazoles present a challenge in patients with non-malignant disorders due to pre-HCT risk for organ dysfunction. Micafungin is an echinocandin with activity against Candida and Aspergillus species. Limited toxicity and drug interactions of micafungin make this an attractive option. Limited experience has been reported in pediatric HCT patients with non-malignant disorders. We report our experience with daily micafungin antifungal prophylaxis in pediatric allo-HCT patients with non-malignant disorders. Methods: A retrospective descriptive analysis of 28 pediatric patients with a variety of non-malignant disorders undergoing allo-HCT and prophylaxis with micafungin is provided. The median age at allo-HCT was 5 years (range, 0.4-11) . No patient had a previous invasive fungal infections, hepatic, or renal dysfunction except for one patient with hepatic fibrosis. Cyclosporine was used for graft-versus-host disease prophylaxis. Results: Table 1 provides a summary of results associated with daily micafungin antifungal prophylaxis. Micafungin was discontinued in one patient due to liver function test abnormalities. A baseline elevation in AST, ALT, and bilirubin was documented in 25%, 39%, and 0% of patients; respectively. There was a two-fold increase in AST, ALT, and bilirubin in 60%, 67%, and 85% of patients during treatment; these decreased on therapy. A similar trend was noted in renal function. Cyclosporine levels did not fluctuate significantly during therapy. Conclusion: Daily micafungin prophylaxis is a well-tolerated method which may prevent fungal infections in pediatric allo-HCT patients with non-malignant disorders. Further study of micafungin prophylaxis to evaluate the efficacy of micafungin in the prevention of fungal infections in pediatric allo-HCT recipients with non-malignant disorders is needed. 
